Research programme: chimeric antigen receptor T cell therapeutics - City of Hope National Medical Center/Mustang Bio

Drug Profile

Research programme: chimeric antigen receptor T cell therapeutics - City of Hope National Medical Center/Mustang Bio

Alternative Names: CAR-T cells - Coronado/City of Hope; CAR-T cells - Mustang Bio; HER2-BBζ CAR-T cells; MB 103; MB 104; MB 105; MB-103 HER2 CAR; MB-104 CS1 CAR; MB-105 PSCA CAR

Latest Information Update: 21 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator City of Hope National Medical Center
  • Developer City of Hope National Medical Center; Mustang Bio
  • Class Antineoplastics; CAR-T cell therapies
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; T lymphocyte replacements; T-cell receptor antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 31 Oct 2017 Mustang Bio plans a first-in-human phase I trial for in 2018
  • 01 Oct 2017 UMass Medicine Science Park and Mustang bio entered into an agreement to support the clinical development and commercialisation of CAR T therapies
  • 14 Jun 2017 Preclinical trials in Cancer (Refractory metastatic disease) in USA (Intraventricular) (Mustang Bio and Fortress Biotech pipeline, June 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top